VANCOUVER, BC / ACCESS Newswire / January 21, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to report final results from a preclinical pig study ...

Cabaletta Bio, Inc. (Nasdaq: CABA) laid out an ambitious 2026 roadmap centered on advancing rese-cel, its experimental CAR T ...

Building on the success of (Vascular Injury in Systemic Diseases: Current Concepts and Future Perspectives, we are pleased to ...

The global, double-blinded phase 3 study enrolled 165 patients aged between 12 and 75 years and measured the time to onset ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces the ...

It's well established that gum disease and rheumatoid arthritis (RA) are strongly linked. But what wasn't known, until a ...

The Department for Work and Pensions has published a full list of 178 conditions that may qualify for the benefit, designed ...

Accelerated by the COVID-19 pandemic, research is now exploring vaccines capable not only of preventing infections, but also ...

The money from the Department for Work and Pensions (DWP) is designed to support households suffering physical and mental ...

Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, releases the following letter to ...

BOSTON, Jan. 20, 2026) ("Tiziana"), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces the peer-reviewed publication of ...